Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares > Seeking alpha
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Comment by Floridas2000on Oct 08, 2016 3:19pm
91 Views
Post# 25325747

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Seeking alpha

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Seeking alpha
kuatolives wrote:


Oh, and one more thing about the deal. Financing for low revenue generating companies is always more expensive than for high ones. This deal also allows ARLZ's EBIDTA to rise to a level that will shave off more % points on their loans when they head to the credit markets. The benefit of this 80M a year in revenue will be immediately felt when they finance... anything.



This is Zack's quote

"Management has indicated that the current credit facilities are a bridge to a more permanent financing situation at some point in the future when the company has significant EBITDA and a leverage ratio that will allow them to receive more favorable financing conditions. "

It appears management does have a plan and are looking to execute it.  12.5% is a good return for Deerfield but in the future Adams should get something better.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities